Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN.

To increase the systemic and mucosal immune responses against the nasally administered tetanus toxoid, liposomes as a drug delivery system and CpG-ODN as an adjuvant were evaluated. Rabbits were nasally immunized with entrapped tetanus toxoid (TT) and CpG-ODN in neutral liposomes and systemic and mucosal immune responses were determined. Liposomes containing TT and CpG-ODN were prepared by dehydration-rehydration method. The volume mean diameter of liposomes was 2.3+/-0.6 microm. Encapsulation efficiency of TT and CpG-ODN was determined as 54.0+/-8.8 and 60.1+/-7.4, respectively. The leakage of the encapsulated TT from liposomes reached 7.38% after 3 months. Encapsulated TT kept its intact structure, and its immunoreactivity was also completely preserved, as shown by SDS-PAGE and ELISA methods. The highest serum IgG and antitoxin titers were observed in groups immunized with solution formulations (P < 0.001). However the highest mucosal sIgA titers were achieved by liposomes encapsulated with TT. CpG-ODN as an adjuvant was able to increase the serum IgG and antitoxin titers when co-administered with TT solution (P < 0.05) or co-encapsulated with TT in liposomes (P < 0.01), but failed to increase the sIgA titers in nasal lavages. No hemolysis occurred on incubation of liposomes and human RBCs. Also after nasal administration of plain liposomes to human volunteers, no local irritation was seen. Intranasal administration of liposomes encapsulated with vaccines showed to be an effective way for inducing the mucosal immune responses.

[1]  Y. Barenholz,et al.  Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. , 2002, Vaccine.

[2]  B O Stuart,et al.  Deposition and clearance of inhaled particles. , 1976, Environmental health perspectives.

[3]  T. Bowersock,et al.  Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. , 2001, Veterinary immunology and immunopathology.

[4]  M. Tafaghodi,et al.  Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Kinam Park,et al.  Oral vaccination with alginate microsphere systems , 1996 .

[6]  R. K. Khar,et al.  Tetanus toxoid loaded 'preformed microspheres' of cross-linked dextran. , 2001, Vaccine.

[7]  E. Jeong,et al.  Development of dried liposome as effective immuno-adjuvant for hepatitis B surface antigen , 1995 .

[8]  A. Krieg,et al.  Immune effects and mechanisms of action of CpG motifs. , 2000, Vaccine.

[9]  H. Davis,et al.  CpG DNA as mucosal adjuvant. , 1999, Vaccine.

[10]  Wayne R. Gombotz,et al.  Protein release from alginate matrices. , 1998, Advanced drug delivery reviews.

[11]  W. Jiskoot,et al.  Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. , 2004, Vaccine.

[12]  Kinam Park,et al.  Immunization of rabbits against a bacterial pathogen with an alginate microparticle vaccine. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Gregory Gregoriadis,et al.  Liposomes As Immunological Adjuvants and Vaccine Carriers , 1996 .

[14]  A. Husband Novel vaccination strategies for the control of mucosal infection. , 1993, Vaccine.

[15]  A. Florence,et al.  A procedure for the efficient entrapment of drugs in dehydration-rehydration liposomes (DRVs) , 1990 .

[16]  J. Mcghee,et al.  The mucosal immune system: from fundamental concepts to vaccine development. , 1992, Vaccine.

[17]  J. Wilschut,et al.  Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. , 1995, Vaccine.

[18]  H. Kiyono,et al.  HIV Mucosal Vaccine: Nasal Immunization with gp160-Encapsulated Hemagglutinating Virus of Japan-Liposome Induces Antigen-Specific CTLs and Neutralizing Antibody Responses1 , 2003, The Journal of Immunology.

[19]  Jafari Nasr Mohammad Reza,et al.  Evaluation of the clearance characteristics of liposomes in the human nose by gamma-scintigraphy , 2005 .

[20]  M. Suckow,et al.  Oral vaccination of animals with antigens encapsulated in alginate microspheres. , 1999, Vaccine.

[21]  J. Swarbrick,et al.  Encyclopedia of Pharmaceutical Technology , 2006 .

[22]  S. Peng,et al.  CpG DNA redirects class‐switching towards "Th1‐like" Ig isotype production via TLR9 and MyD88 , 2004, European journal of immunology.

[23]  A. R. Thomson,et al.  Uptake of Small Resin Particles (1–5µ Diameter) by the Alimentary Canal of the Calf , 1960, Nature.

[24]  J. Wilschut,et al.  Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. , 1995, Vaccine.

[25]  P. Edman,et al.  Characterization of degradable starch microspheres as a nasal delivery system for drugs , 1990 .

[26]  H. Alpar,et al.  Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid , 1992 .

[27]  J. Dokmetjian,et al.  A possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin. , 2000, Vaccine.